Bold Therapeutics, Inc.
https://www.bold-therapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bold Therapeutics, Inc.
Bold Plans Pivotal GI Cancer Studies After Phase II Success
The private Canadian biotech is advancing a first-in-class GRP78 inhibitor into Phase III studies in gastrointestinal cancers after interim Phase II data suggested potential to improve upon on standard-of-care efficacy.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice